DLL3 and small cell lung carcinoma: While rovalpituzumab tesirine (Rova-T) failed in clinical trials, the DLL3-targeting bispecific T-cell engager tarlatamab has recently gained accelerated FDA approval, showing promise in SCLC treatment [67,68].